• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

    9/17/24 11:22:47 AM ET
    $AZN
    $BLTE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, September 24 and Wednesday, September 25, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in China, France, Hong Kong, Netherlands, Philippines, Portugal, Spain, Switzerland, and the United Kingdom will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies.

    There is no fee for participants to log in, attend live presentations and/or ask questions.

    Pre-registration is suggested. Please register here: www.adr.db.com/dbvic

    September 24 Agenda (US Eastern Standard Time):

    • 8:00 AM: First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • 8:30 AM: Lotus Technology Inc (NASDAQ:LOT)
    • 9:00 AM: HUTCHMED (China) Limited ((AIM: HCM, NASDAQ:HCM, and HKEX:13))
    • 9:30 AM: iHuman Inc. (NYSE:IH)
    • 10:00 AM: Marks and Spencer ((LSE: MKS, OTC:MAKSY)
    • 10:30 AM: SSE plc ((LSE: SSE, OTC:SSEZY)
    • 11:00 AM: BDO Unibank, Inc ((PSE: BDO, OTC:BDOUY)
    • 11:30 AM: AstraZeneca plc ((LSE: AZN, NASDAQ:AZN)

    September 25 Agenda (US Eastern Standard Time):

    • 8:00 AM: Yiren Digital Ltd (NYSE:YRD)
    • 8:30 AM: KPN ((Euronext Amsterdam: KPN, OTC:KKPNY)
    • 9:00 AM: Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • 9:30 AM: Carrefour S.A. (PARIS:CA, OTC:CRRFY)
    • 10:00 AM: EDP Group ((Euronext Lisbon: EDP, OTC:EDPFY)
    • 10:30 AM: Repsol S.A ((BMAD: REP, OTC:REPYY)
    • 11:00 AM: Belite Bio, Inc  (NASDAQ:BLTE)
    • 11:30 AM: DSM-Firmenich AG ((DSFIR:AEX, OTC:DSFIY)

    The presentations will be available for replay after the Conference.

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    For further information, please contact:

    Dylan Riddle

    Deutsche Bank AG

    Press & Media Relations

    Tel. +12122504982

    Cell. +1(904)3866481

    Email [email protected]

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© September 2024 Deutsche Bank AG. All rights reserved.



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $BLTE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    More analyst ratings

    $AZN
    $BLTE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Belite Bio with a new price target

    Cantor Fitzgerald resumed coverage of Belite Bio with a rating of Overweight and set a new price target of $154.00

    11/24/25 8:35:36 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Belite Bio with a new price target

    Mizuho initiated coverage of Belite Bio with a rating of Neutral and set a new price target of $105.00

    11/20/25 8:06:38 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lotus Tech Debuts its First PHEV, Advancing into Wider Markets

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (the "Company") (NASDAQ:LOT) today provided an update on its new plug-in hybrid (PHEV) model. The model made its public debut on December 5, 2025 through inclusion in the Ministry of Industry and Information Technology of PRC's new-vehicle catalogue. As the first PHEV in Lotus' 77-year history, this marks a key milestone in the brand's electrification roadmap and reflects its commitment to meet growing consumer demand across diversified powertrain segments. Official launch of the model in China is scheduled in the first quarter of 2026, with a dedicated technology preview event planned for January 2026. Overseas rollouts wi

    12/12/25 7:00:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Yiren Digital Wins "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards

    BEIJING, Dec. 11, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading Fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, today announced it has been awarded the "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards. The award was presented during the 2025 China Financial Annual Conference, held in Beijing and co-hosted by the China Stock Exchange Executive Council and the leading financial media Hexun.com. The conference, themed "Charting a Breakthrough for China's Economy," brought together over twent

    12/11/25 2:40:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer

    The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer following treatment with first-line platinum-based chemotherapy in combination with bevacizumab. DESTINY-Ovarian01 is being conducted in collaboration with the European Network of Gynecological Oncological Trial Groups (ENGOT), with the Spanish cooperative group (GEICO) as the lead ENGOT group, The GOG Foundation, Inc. (GOG-F) and Asia-Pacific Gynecologic Oncol

    12/9/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Belite Bio Inc

    SCHEDULE 13G - BELITE BIO, INC (0001889109) (Subject)

    12/10/25 4:30:21 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    12/8/25 6:02:53 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    12/4/25 1:48:33 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    View All

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BLTE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/8/24 6:04:35 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    $AZN
    $BLTE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    View All

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

    Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in a global Phase 3 trial for Stargardt disease, achieving a statistically significant p-value of 0.0033Tinlarebant met the primary efficacy endpoint, demonstrating clinical benefit by significantly reducing the lesion growth rate by 36% compared to placebo, as measured by retinal imagingTinlarebant was well tolerated throughout the trial Stargardt disease impacts more than 50,000 patients in the U.S. Belite Bio plans to file an NDA with the US FDA in 1H 2026Company will host a conference call and webcast today at 8:00 a.m. ET SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite

    12/1/25 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yiren Digital Reports Third Quarter 2025 Financial Results

    BEIJING, Nov. 25, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, today announced its unaudited financial results for the quarter ended September 30, 2025. Third Quarter 2025 Operational Highlights Financial Services Business Total loans facilitated in the third quarter of 2025 reached RMB20.2 billion (US$2.8 billion), representing an increase of 51% compared to RMB13.4 billion in the same period of 2024 and remaining stable compared to RMB20.3 billion in the second quarter of 2025.Cumulative number of borro

    11/25/25 5:30:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance